Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia. More than 6 million Americans are diagnosed with dementia each ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia.. The active ingredient in ...

The unexpected ways Ozempic-like drugs might fight dementia. They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Talk about a lucky charm. Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight loss as well as ease ...

Ozempic Might Be a Dementia Buster, Too Like semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro) before it, MariTide mimics GLP-1, a hormone important to regulating our hunger ...

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...